• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Flynn James E converted options into 85,153 shares

    11/16/21 9:34:54 PM ET
    $DFPH
    Business Services
    Finance
    Get the next $DFPH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Flynn James E

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Oncology Institute, Inc. [ DFPH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) X Other (specify below)
    Possible Members of 10% Group
    3. Date of Earliest Transaction (Month/Day/Year)
    11/12/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 11/12/2021 C(1) 40 A (1) 40 I Through DFP Sponsor, LLC(2)(3)
    Class A Common Stock 11/12/2021 C(1) 85,113 A (1) 85,113 I Through Deerfield Management Company, L.P.(2)(3)(4)
    Class A Common Stock 1,605,477 I Through Deerfield Partners, L.P.(2)(3)
    Class A Common Stock 1,605,477 I Through Deerfield Private Design Fund IV, L.P.(2)(3)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Series A Common Stock Equivalent Convertible Preferred Stock (5) 11/12/2021 P 50,000 (5) (5) Class A Common Stock 5,000,000 $1,000 58,945 I Through Deerfield Partners, L.P.(2)(3)
    Series A Common Stock Equivalent Convertible Preferred Stock (5) 11/12/2021 P 50,000 (5) (5) Class A Common Stock 5,000,000 $1,000 58,945 I Through Deerfield Private Design Fund IV, L.P.(2)(3)
    Series A Common Stock Equivalent Convertible Preferred Stock (5) (5) (5) Class A Common Stock 4,562,000 45,620 I Through DFP Sponsor, LLC(2)(3)
    Class B Common Stock (6) 11/12/2021 J(7) 707,960 (6) (6) Class A Common Stock 707,960 $0.00 40 I Through DFP Sponsor, LLC(2)(3)
    Class B Common Stock (6) 11/12/2021 J(7) 14,887 (6) (6) Class A Common Stock 14,887 $0.00 85,113 I Through Deerfield Management Company, L.P.(2)(3)(4)
    Class B Common Stock (6) 11/12/2021 C(1) 40 (6) (6) Class A Common Stock 40 $0.00 0 I Through DFP Sponsor, LLC(2)(3)
    Class B Common Stock (6) 11/12/2021 C(1) 85,113 (6) (6) Class A Common Stock 85,113 $0.00 0 I Through Deerfield Management Company, L.P.(2)(3)(4)
    Private Placement Warrants $11.5 11/12/2021 J(8) 3,177,543 12/12/2021 11/12/2026 Class A Common Stock 3,177,543(8) (8) 3,177,543(8) I Through DFP Sponsor, LLC(2)(3)
    Public Warrants $11.5 11/12/2021 J(9) 625,000 12/12/2021 11/12/2026 Class A Common Stock 625,000(9) (9) 625,000(9) I Through Deerfield Partners, L.P.(2)(3)
    Public Warrants $11.5 11/12/2021 J(9) 625,000 12/12/2021 11/12/2026 Class A Common Stock 625,000(9) (9) 625,000(9) I Through Deerfield Private Design Fund IV, L.P.(2)(3)
    1. Name and Address of Reporting Person*
    Flynn James E

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Deerfield Mgmt L.P.

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    DEERFIELD PARTNERS, L.P.

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Deerfield Mgmt IV, L.P.

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Deerfield Private Design Fund IV, L.P.

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)
    Explanation of Responses:
    1. Upon the closing of the Issuer's initial business combination, each share of Class B Common Stock converted (automatically in accordance with its terms) into one share of Class A Common Stock for no consideration.
    2. This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. ("Deerfield Partners"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. ("Fund IV" and, together with Deerfield Partners, the "Funds"). Deerfield Management Company, L.P. ("Deerfield Management") is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt IV, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P. Each Fund holds a 37% membership interest in DFP Sponsor, LLC (the "Sponsor").
    3. In accordance with Instruction 4(b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds, the Sponsor and Deerfield Management is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
    4. Steven Hochberg, a partner in Deerfield Management, served as a director and the chief executive officer of the Issuer until his resignation from such positions on November 12, 2021 (prior to the vote of the Issuer's stockholders in respect of the consummation of the Issuer's initial business combination and prior to the transactions reported herein). The Class A Common Stock owned by Steven Hochberg and reported herein is held for the benefit, and at the direction, of Deerfield Management.
    5. Each share of Series A Common Stock Equivalent Convertible Preferred Stock ("Common Equivalent Preferred Stock") is convertible into 100 shares of Class A Common Stock (subject to adjustment) at any time and from time to time at the election of the holder thereof. The Common Equivalent Preferred Stock has no expiration date. The terms of the Common Equivalent Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Class A Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of Class A Common Stock then outstanding.
    6. The shares of Class B Common Stock were convertible into shares of the Issuer's Class A Common Stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-236578) and had no expiration date.
    7. In connection with, and immediately prior to, the closing of the Issuer's initial business combination, pursuant to the Stockholder Support Agreement, dated as of June 28, 2021, DFP Sponsor, LLC (the "Sponsor") forfeited 707,960 shares of Class B Common Stock and Steven Hochberg forfeited 14,887 shares of Class B Common Stock for no consideration.
    8. The Sponsor acquired the Private Placement Warrants from the Issuer in connection with the Issuer's initial public offering on March 13, 2020. As a result of the closing of the Business Combination, the Private Placement Warrants will become exercisable as of the date that is 30 days after the closing of the Issuer's initial business combination (i.e., November 12, 2021). The Private Placement Warrants will expire on November 12, 2026 or earlier upon redemption or liquidation. Prior to the closing of the Issuer's initial business combination, the Sponsor elected to be governed by a Maximum Percentage (as defined in the Private Placement Warrants) of 4.9%.
    9. Each Fund acquired the Public Warrants from the Issuer in connection with the Issuer's initial public offering on March 13, 2020. As a result of the closing of the Issuer's initial business combination, the Public Warrants will become exercisable as of the date that is 30 days after the closing of the Issuer's initial business combination (i.e., November 12, 2021). The Public Warrants will expire on November 12, 2026 or earlier upon redemption or liquidation. Prior to the closing of the Issuer's initial business combination, each fund elected to be governed by a Maximum Percentage (as defined in the Public Warrants) of 4.9%.
    Remarks:
    Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn
    /s/ Jonathan Isler, Attorney-in-Fact 11/16/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $DFPH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DFPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DFPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3: New insider M33 Growth I L.P. claimed ownership of 15,256,383 shares

    3 - Oncology Institute, Inc. (0001799191) (Issuer)

    11/22/21 4:38:03 PM ET
    $DFPH
    Business Services
    Finance

    SEC Form 3: New insider Havencrest Healthcare Partners, L.P. claimed ownership of 15,662,794 shares

    3 - Oncology Institute, Inc. (0001799191) (Issuer)

    11/22/21 4:28:08 PM ET
    $DFPH
    Business Services
    Finance

    SEC Form 4: Sarin Ravi Yang was granted 4,109,771 shares (Amendment)

    4/A - Oncology Institute, Inc. (0001799191) (Issuer)

    11/22/21 4:15:17 PM ET
    $DFPH
    Business Services
    Finance

    $DFPH
    SEC Filings

    View All

    $DFPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DFP Healthcare Acquisitions Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits (Amendment)

    8-K/A - Oncology Institute, Inc. (0001799191) (Filer)

    11/22/21 5:18:03 PM ET
    $DFPH
    Business Services
    Finance

    DFP Healthcare Acquisitions Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Change in Shell Company Status, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Registrant’s Certifying Accountant, Changes in Control of Registrant, Leadership Update, Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics, Other Events, Financial Statements and Exhibits

    8-K - Oncology Institute, Inc. (0001799191) (Filer)

    11/18/21 5:29:51 PM ET
    $DFPH
    Business Services
    Finance

    SEC Form 25-NSE filed by DFP Healthcare Acquisitions Corp.

    25-NSE - DFP HEALTHCARE ACQUISITIONS CORP. (0001799191) (Subject)

    11/12/21 4:20:20 PM ET
    $DFPH
    Business Services
    Finance

    The Oncology Institute Physician, Dr. John Khoury, Receives 40 Under 40 in Cancer Award

    This is the second year in a row a TOI physician was recognized The Oncology Institute (TOI) is proud to announce that Dr. John Khoury was recently awarded the "40 Under 40 in Cancer" award by the Association for Value-Based Cancer Care. This is the second year in a row a TOI physician was recognized for this honor. Dr. Omkar Marathe was selected for the distinction in 2020. "It's an honor to be part of such a distinguished list of young oncology professionals and leaders who work very hard to improve the lives of those affected by cancer," said Dr. Khoury. Dr. John Khoury is a triple board-certified physician who joined The Oncology Institute in 2020. He completed his residency and fell

    11/9/21 9:15:00 AM ET
    $DFPH
    Business Services
    Finance

    DFP Healthcare Acquisitions Corp. Announces Special Meeting Date to Approve Proposed Business Combination with The Oncology Institute

    Special Meeting of Stockholders Scheduled for November 12, 2021 DFP Healthcare Acquisitions Corp. ("DFP") (NASDAQ:DFPH) announced today that it has scheduled the special meeting of its stockholders (the "Special Meeting") for November 12, 2021 at 10:00 a.m., Eastern Time, to approve the proposed business combination (the "Business Combination") with The Oncology Institute ("TOI" or the "Company"), the U.S. market leader in providing value-based oncology care. DFP also announced that it has filed its definitive proxy statement/prospectus for the Special Meeting and has commenced mailing the definitive proxy statement/prospectus to its stockholders of record as of September 23, 2021, the re

    10/22/21 4:05:00 PM ET
    $DFPH
    Business Services
    Finance

    The Oncology Institute of Hope and Innovation (TOI) Expands to San Diego County

    Two state-of-the-art clinics opening in Vista and Chula Vista with a third in Hillcrest slated for later this year The Oncology Institute of Hope and Innovation (TOI) began seeing patients this week at two new locations in Vista and Chula Vista, marking the community-based oncology provider's entry into San Diego County. A third location in Hillcrest is slated to open in the fall. Founded in 2007, TOI is a multi-state cancer care practice dedicated to healing and empowering patients through compassion, innovation, and state-of-the-art medical care. TOI is the largest value-based oncology practice in the U.S., taking accountability for both the quality outcomes as well as the medical costs

    8/4/21 12:05:00 PM ET
    $DFPH
    Business Services
    Finance

    $DFPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by DFP Healthcare Acquisitions Corp.

    SC 13D - Oncology Institute, Inc. (0001799191) (Subject)

    11/22/21 4:41:54 PM ET
    $DFPH
    Business Services
    Finance

    SEC Form SC 13D filed by DFP Healthcare Acquisitions Corp.

    SC 13D - Oncology Institute, Inc. (0001799191) (Subject)

    11/22/21 4:25:01 PM ET
    $DFPH
    Business Services
    Finance

    SEC Form SC 13D filed by DFP Healthcare Acquisitions Corp.

    SC 13D - Oncology Institute, Inc. (0001799191) (Subject)

    11/22/21 4:19:36 PM ET
    $DFPH
    Business Services
    Finance